# Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2

> **NCT05555589** · PHASE3 · RECRUITING · sponsor: **ReGenTree, LLC** · enrollment: 70 (estimated)

## Conditions studied

- Neurotrophic Keratopathy

## Interventions

- **DRUG:** RGN-259
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05555589
- **Lead sponsor:** ReGenTree, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-11
- **Primary completion:** 2026-04-30
- **Final completion:** 2026-05-30
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2025-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05555589

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05555589, "Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT05555589. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*